eligibility_summary
Eligible: de novo, untreated LBCL per WHO 2022 (DLBCL NOS [GCB/ABC], HGBL-MYC/BCL2, HGBL NOS, THRLBCL, EBV+ DLBCL), IPI 1–2 with LDH >1.3×ULN and/or bulky ≥7 cm, or IPI ≥3, measurable disease per Lugano, Ann Arbor stage II–IV. Exclude: significant comorbidity/infection, other lymphoma subtypes (e.g., PMBCL, cutaneous leg-type DLBCL, grade 3b FL, transformed, ALK+, effusion, Burkitt), CNS involvement, other protocol criteria.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 3 trial in previously untreated high‑risk large B‑cell lymphoma compares golcadomide (BMS‑986369/CC‑99282) + R‑CHOP vs placebo + R‑CHOP. Golcadomide is an oral CELMoD (cereblon E3 ligase modulator) that binds CRBN to induce degradation of IKZF1/IKZF3, activating T/NK cells, enhancing ADCC, and suppressing IRF4/MYC in malignant B cells. R‑CHOP: rituximab (anti‑CD20 mAb, B‑cell depletion via CDC/ADCC/apoptosis), cyclophosphamide (alkylator, DNA crosslinking), doxorubicin (anthracycline, topoisomerase II inhibition/ROS), vincristine (vinca alkaloid, microtubule inhibition), prednisone (glucocorticoid, lymphocyte apoptosis). Targets: CD20+ B cells, CRBN–IKZF1/3 axis, T/NK effector function, DNA damage/repair, topo II, mitotic spindle, glucocorticoid signaling.